ANAB
AnaptysBio, Inc.
There isn't enough reported data to score ANAB yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ANAB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
ANAB's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ANAB PE Valuation
ANAB has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 5.3x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ANAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ANAB to return to profit, with revenue growing. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ANAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.01 | — |
| Q1 2026 | -$1.02 | +$3.74 |
| Q4 2025 | -$0.46 | +$4.66 |
| Q3 2025 | -$2.73 | +$3.35 |
| Q2 2025 | -$4.39 | +$1.96 |
| Q1 2025 | -$4.76 | +$1.38 |
| Q4 2024 | -$5.12 | +$0.96 |
| Q3 2024 | -$6.08 | -$0.66 |
| Q2 2024 | -$6.35 | -$1.16 |
ANAB has the stronger earnings trend. Trailing diluted EPS is down 121% for ANAB versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ANAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30.3M | -60% |
| Q1 2026 | $25.6M | -8% |
| Q4 2025 | $108.2M | +151% |
| Q3 2025 | $76.3M | +154% |
| Q2 2025 | $22.3M | +103% |
| Q1 2025 | $27.8M | +287% |
| Q4 2024 | $43.1M | +379% |
| Q3 2024 | $30M | +805% |
HIMS has the stronger quarterly revenue trend. Revenue is up 36% for ANAB versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +20 points |
| Q1 2026 | -136% | -36 points |
| Q4 2025 | 62% | +84 points |
| Q3 2025 | 45% | +121 points |
| Q2 2025 | -118% | +250 points |
| Q1 2025 | -99% | +489 points |
| Q4 2024 | -22% | +446 points |
| Q3 2024 | -76% | +1061 points |
ANAB has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ANAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.5M | +$17.8M |
| Q1 2026 | -$25.9M | -$15.2M |
| Q4 2025 | $98M | +$164.9M |
| Q3 2025 | -$27.4M | -$17.2M |
| Q2 2025 | -$40.3M | -$18.9M |
| Q1 2025 | -$10.7M | +$26.5M |
| Q4 2024 | -$66.9M | -$32.3M |
| Q3 2024 | -$10.1M | +$26.5M |
ANAB has the stronger cash trend. Its trailing FCF is up 149% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ANAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +22% | +6.4M shares |
| 1 year | +22% | +6.3M shares |
| 3 years | +32% | +8.4M shares |
| 5 years | +28% | +7.7M shares |
| Available history | +30% | +8M shares |
ANAB has 35M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $3.4M |
| Q3 2025 | $9.7M |
| Q2 2025 | $51.1M |
| Q1 2025 | $4.4M |
| Q4 2024 | $456,000 |
| Q3 2024 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ANAB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ANAB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -6.0x | Net Cash |
| Q4 2025 | -4.9x | Net Cash |
| Q3 2021 | -40.6x | Net Cash |
ANAB has the edge over HIMS on leverage, with a lower net debt burden relative to earnings.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ANAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.4 | Neutral |
| Stochastic | 21.4 | Neutral |
ANAB's weekly RSI is 45 (neutral) and its Stochastic is 21 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ANAB PE vs Healthcare Sector
| Metric | ANAB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ANAB has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ANAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $47.9 | 0.3% below |
| 20 week MA | $53.7 | 11% below |
| 50 week MA | $47.7 | 0.1% above |
| 100 week MA | $31.5 | 52% above |
| 200 week MA | $23.5 | 103% above |
ANAB has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ANAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.2 | $14.8 | +33% |
| 2021 | $14.8 | $24.7 | +67% |
| 2022 | $24.7 | $19.5 | -21% |
| 2023 | $19.5 | $14.3 | -27% |
| 2024 | $14.3 | $8.69 | -39% |
| 2025 | $8.69 | $33.4 | +284% |
| 2026 YTD | $33.4 | $47.8 | +43% |
ANAB has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.